GTHX vs. FHTX, IMMP, GBIO, ACRV, MACK, PRLD, OVID, QURE, GALT, and CDT
Should you be buying G1 Therapeutics stock or one of its competitors? The main competitors of G1 Therapeutics include Foghorn Therapeutics (FHTX), Immutep (IMMP), Generation Bio (GBIO), Acrivon Therapeutics (ACRV), Merrimack Pharmaceuticals (MACK), Prelude Therapeutics (PRLD), Ovid Therapeutics (OVID), uniQure (QURE), Galectin Therapeutics (GALT), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical preparations" industry.
Foghorn Therapeutics (NASDAQ:FHTX) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
In the previous week, G1 Therapeutics had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 3 mentions for G1 Therapeutics and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.01 beat G1 Therapeutics' score of 0.00 indicating that G1 Therapeutics is being referred to more favorably in the news media.
Foghorn Therapeutics presently has a consensus target price of $14.50, suggesting a potential upside of 157.55%. G1 Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 148.89%. Given G1 Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Foghorn Therapeutics is more favorable than G1 Therapeutics.
G1 Therapeutics has a net margin of -58.13% compared to G1 Therapeutics' net margin of -288.17%. G1 Therapeutics' return on equity of 0.00% beat Foghorn Therapeutics' return on equity.
61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are owned by institutional investors. 9.2% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 8.2% of G1 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
G1 Therapeutics received 274 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 65.66% of users gave G1 Therapeutics an outperform vote while only 57.69% of users gave Foghorn Therapeutics an outperform vote.
G1 Therapeutics has higher revenue and earnings than Foghorn Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Foghorn Therapeutics has a beta of 3.13, meaning that its share price is 213% more volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
Summary
Foghorn Therapeutics and G1 Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get G1 Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
G1 Therapeutics Competitors List
Related Companies and Tools
